As the COVID-19 pandemic continues to spread, scientists and health care providers are seeking ways to keep the coronavirus from infecting tissues once they're exposed. A new study suggests luring the virus with a decoy -- an engineered, free-floating receptor protein - binds the virus and blocks infection.
Since the discovery of COVID-19, a warlike analogy is frequently used to define our interaction with the virus, but in many ways we may be at war with ourselves.
Yunjeong Kim and Kyeong-Ok 'KC' Chang, virologists in the College of Veterinary Medicine at Kansas State University, have published a study showing a possible therapeutic treatment for COVID-19.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women. The study is currently available in Proceedings of National Academy of Sciences.
The University of Kent's School of Biosciences and the Institute of Medical Virology at Goethe-University, Frankfurt am Main, have identified that a glycoprotein known as transferrin may critically contribute to severe forms of COVID-19.
New genetic and patient analyses suggest severe COVID is linked to overactive complement, one of the immune system's oldest branches, and excess blood clotting.
On July 27 2020, the US Department of Health and Human Services' (HHS) Health Resources and Services Administration (HRSA) launched a Special Collection of manuscripts across the open-access journals PLOS Medicine and PLOS ONE, highlighting Ryan White HIV/AIDS Program's (RWHAP) innovative approaches for data utilization and engagement of people with HIV who are not in care and not virally suppressed.
The new discovery could have important implications for brain infections, neurodegenerative diseases and autoimmune disorders.
A leading COVID-19 vaccine candidate, developed at Beth Israel Deaconess Medical Center, creates the groundwork for a newly launched COVID-19 vaccine clinical trial.
To fight viruses, cells can deploy defence enzymes that progressively destroy viral genome. However, this degradation mechanism is not effective against epidemic viruses like Zika. In fact, the defence enzyme jams at precise points of the viral genome, which assumes a "defensive" conformation. This is how the virus succeeds at protecting important pieces of its RNA inside infected cells, as demonstrated by a recent study coordinated by SISSA and published in Nature Communications.